Observations that peritoneal dialysis (PD) may be an effective, lower-cost alternative to hemodialysis for the treatment of ESKD have led to policies encouraging PD and subsequent increases in its use in the United States.
Vaccines and other biomedical advances will not be sufficient to halt COVID-19, unless we simultaneously counter anti-science aggression, writes Peter Hotez, fellow in disease and poverty, in a new article for PLOS Biology.
The authors found that six months of pre–end-stage kidney disease nephrology care did not significantly improve the likelihood that patients would remain employed when they started dialysis. This finding underscores the need to identify effective methods to help patients stay employed when they transition to dialysis.
Expanded “payment bundles” for the treatment of end stage kidney disease did not in general increase the risk of closure by dialysis facilities, the authors conclude.
Sayna Norouzi, Bo Zhao, Ahmed Awan, Wolfgang Winkelmayer, Vivian Ho, Kevin EricksonFebruary 5, 2020
Consolidated dialysis markets have coincided with both positive and negative trends in health care costs and outcomes. If the underlying mechanisms that contributed to past consolidation persist, dialysis markets may remain highly concentrated over the long term.
Maryam Saeed, Vivian Ho, Kevin EricksonJanuary 12, 2020